id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0124-0008,FDA,FDA-2006-E-0124,USPTO - Certificate Extending Patent Term,Other,CEP-Certificate Extending Patent Term,2009-02-04T05:00:00Z,2009,2,2009-02-04T05:00:00Z,,2009-02-04T15:28:14Z,,0,0,0900006480607d65
FDA-2006-E-0124-0009,FDA,FDA-2006-E-0124,USPTO to Pfizer Inc. - Notice of Final Determination,Other,LET-Letter,2009-02-04T05:00:00Z,2009,2,2009-02-04T05:00:00Z,,2009-02-04T15:28:15Z,,0,0,0900006480843ef1
FDA-2006-E-0124-0007,FDA,FDA-2006-E-0124,Pfizer Inc. -  Patent Term Extension Application,Other,APP-Application,2009-02-04T05:00:00Z,2009,2,2009-02-04T05:00:00Z,,2009-02-04T15:28:12Z,,0,0,09000064804501b1
FDA-2006-E-0124-0006,FDA,FDA-2006-E-0124,FDA/CDER to the USPTO - Letter,Other,LET-Letter,2007-05-16T04:00:00Z,2007,5,,,2008-05-30T16:47:04Z,,0,0,09000064804501b6
FDA-2006-E-0124-0005,FDA,FDA-2006-E-0124,Determination of Regulatory Review Period for Purposes of Patent Extension; DRAXXIN - Federal Register Notice,Notice,N-Notice,2006-10-03T04:00:00Z,2006,10,2006-09-29T04:00:00Z,2006-12-02T04:59:59Z,2008-05-30T16:45:01Z,,0,0,09000064804501b5
FDA-2006-E-0124-0004,FDA,FDA-2006-E-0124,FDA/CDER to the USPTO - Letter,Other,LET-Letter,2006-09-11T04:00:00Z,2006,9,,,2008-05-30T16:34:38Z,,0,0,09000064804501b4
FDA-2006-E-0124-0003,FDA,FDA-2006-E-0124,USPTO to FDA/CDER - Letter,Other,LET-Letter,2006-07-12T04:00:00Z,2006,7,,,2008-05-30T16:31:42Z,,0,0,09000064804501b3
FDA-2006-E-0124-0002,FDA,FDA-2006-E-0124,FDA/CDER to the USPTO - Letter,Other,LET-Letter,2006-02-28T05:00:00Z,2006,2,,,2008-05-30T16:33:08Z,,0,0,09000064804501b2
FDA-2006-E-0124-0001,FDA,FDA-2006-E-0124,USPTO to FDA/CDER - Letter,Other,LET-Letter,2006-01-06T05:00:00Z,2006,1,,,2008-05-30T16:32:29Z,,0,0,09000064804501a9